Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET rearrange |
Therapy | RXDX-105 |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET rearrange | lung non-small cell carcinoma | predicted - sensitive | RXDX-105 | Case Reports/Case Series | Actionable | In a clinical case study, a patient with non-small cell lung cancer harboring a RET rearrangement demonstrated a sustained partial response following treatment with RXDX-105 (CEP-32496) on a Phase Ib clinical trial (PMID: 28011461; NCT01877811). | 28011461 |
RET rearrange | lung non-small cell carcinoma | predicted - sensitive | RXDX-105 | Phase I | Actionable | In a Phase Ib trial, treatment with RXDX-105 (CEP-32496) resulted in an overall response rate of 19% (6/31) and stable disease in 39% (12/31) of patients with treatment-naive non-small cell lung cancer harboring a RET fusion (PMID: 30487236; NCT01877811) | 30487236 |
PubMed Id | Reference Title | Details |
---|---|---|
(28011461) | Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. | Full reference... |
(30487236) | A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. | Full reference... |